Related references
Note: Only part of the references are listed.Therapeutic Potential of Cone Snail Venom Peptides (Conopeptides)
Irina Vetter et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2012)
Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases
Victor Chi et al.
TOXICON (2012)
Spider-venom peptides that target voltage-gated sodium channels: Pharmacological tools and potential therapeutic leads
Julie K. Klint et al.
TOXICON (2012)
Durable Pharmacological Responses from the Peptide ShK-186, a Specific Kv1.3 Channel Inhibitor That Suppresses T Cell Mediators of Autoimmune Disease
Eric J. Tarcha et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Venoms as a platform for human drugs: translating toxins into therapeutics
Glenn F. King
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
The Beneficial Effect of Blocking Kv1.3 in the Psoriasiform SCID Mouse Model
Amos Gilhar et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
The DTH effector response and IL-2 are unaffected by cyclosporine A in autoimmune B6D2F1 mice
Heather MacLeod et al.
CELLULAR IMMUNOLOGY (2010)
The functional network of ion channels in T lymphocytes
Michael D. Cahalan et al.
IMMUNOLOGICAL REVIEWS (2009)
Imaging of Effector Memory T Cells during a Delayed-Type Hypersensitivity Reaction and Suppression by Kv1.3 Channel Block
Melanie P. Matheu et al.
IMMUNITY (2008)
OdK2, a Kv1.3 channel-selective toxin from the venom of the Iranian scorpion Odonthobuthus doriae
Yousra Abdel-Mottaleb et al.
TOXICON (2008)
Opinion - How many drug targets are there?
John P. Overington et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases
Christine Beeton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Long-term survival of an allografted submandibular gland in a miniature swine model given immunosuppressant drugs
XY Ge et al.
BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY (2006)
Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases
A Schmitz et al.
MOLECULAR PHARMACOLOGY (2005)
Tacrolimus versus cyclosporine induction therapy in pulmonary transplantation in miniature swine
G Warnecke et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2005)
The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain
H Rus et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Kv1-3 potassium channel blockade as an approach to insulin resistance
GV Desir
EXPERT OPINION ON THERAPEUTIC TARGETS (2005)
Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases
C Beeton et al.
MOLECULAR PHARMACOLOGY (2005)
K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom
S Mouhat et al.
BIOCHEMICAL JOURNAL (2005)
Intrathecal ziconotide for refractory pain
SA Doggrell
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2004)
Immunization with an interferon-γ-gp120 fusion protein induces enhanced immune responses to human immunodeficiency virus gp120
AL McCormick et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
Selective blockade of T lymphocyte K+ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis
C Beeton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation
C Beeton et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
